Skip to content

Home
Insights
Brochures
Careers
About us
News

Home
Insights
Brochures
Careers
About us
News

Pharma News

Highlights from the week of 11th May - 18th May Fosun Pharma ( Collaboration ) Fosun Pharma and AriBio sign an exclusive global agreement for the development, registration, manufacturing and commercialization of AR1001, a phosphodiesterase-5 inhibitor with disease-modifying potential to treat AD Alkermes ( Phase 3, Results ) Phase 3 REVITALYZ study of Alkermes evaluating LUMRYZ extended-release oral suspension in adults with idiopathic hypersomnia demonstrates significant improvements in excessive daytime sleepiness compared to placebo AstraZeneca ( Phase 3, Results ) AstraZeneca's VOLGA Phase 3 trial evaluating IMFINZI in combination with neoadjuvant enfortumab vedotin demonstrates clinically meaningful improvements in EFS and OS in muscle-invasive bladder cancer AstraZeneca ( Phase 3, Results ) The CALYPSO Phase 3 trial from AstraZeneca assessing AZP-3601 demonstrates clinically meaningful normalization of sCa levels and independence from active vitamin D and oral calcium supplements in adults with chronic HypoPT at week 24 All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 11th May – 18th May in the world of pharma and healthcare!

May 18, 2026

Highlights from the week of 4th May - 11th May Lannett ( FDA, Approval ) FDA approves Lanex Biologics’ subsidiary Lannett and Sunshine Lake Pharma's interchangeable biosimilar, LANGLARA, to treat adult and pediatric patients with type 1 diabetes mellitus and adults with type 2 diabetes mellitus Bristol Myers Squibb ( EU, Approval ) EC grants approval to Bristol Myers Squibb's SOTYKTU, a once-daily, oral, selective TYK2 inhibitor to treat active PsA in adults with inadequate or intolerant response to DMARD therapy Biocon ( Health Canada, Approval ) Biocon gets Health Canada approval for its micafungin injection, USP, 50 mg and 100 mg for the treatment and as a prophylaxis of various Candida infections in patients undergoing hematopoietic stem cell transplantation Merck ( Acquisition ) Merck acquires Terns Pharmaceuticals along with its Breakthrough Therapy Designation drug TERN-701, a potential treatment option for certain patients with chronic myeloid leukemia All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 04th May – 11th May in the world of pharma and healthcare!

May 11, 2026

Highlights from the Week of 27th April 2026 - 4th May 2026 ( FDA, Approval ) AstraZeneca's fixed-dose triple-combination therapy, BREZTRI AEROSPHERE, gains FDA approval for the maintenance treatment of asthma in patients aged 12 and older ( FDA, Approval ) Arvinas' VEPPANU receives FDA approval as the first-ever PROTAC therapy for the treatment of adults with ER+ or HER2- or ESR1 mutated, advanced or metastatic breast cancer ( FDA, Approval ) FDA approves Incyte's JAKAFI XR extended-release tablets to treat adults with intermediate- or high-risk myelofibrosis, polycythemia vera and adults or children who are 12 years and older with GVHD ( FDA, Approval ) Axsome secures approval from the FDA for its AUVELITY, targeting NMDA and sigma-1 receptors to treat dementia due to Alzheimer's disease Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 27th April 2026 – 4th May 2026 in the world of pharma and healthcare!

May 5, 2026

« Previous Page1 Page2 Page3 Page4 Page5 Next »

Investor calendar

Goldman Sachs 47th Annual Global Healthcare Conference June 08,2026 To June 10,2026 June 08 June 09 June 10 All logos and trademarks remain the intellectual properties of their respective owners

Attention stay up to date with the latest investor calls by checking out our calendar for the week of June 08,2026 To June 10,2026

June 9, 2026

INVESTOR CALENDER OF THE WEEK June 01,2026 To June 04,2026 Investor Event at ASCO 2026 June 01 June 02 Jefferies Global Healthcare Conference June 03 June 04

Attention stay up to date with the latest investor calls by checking out our calendar for the week of June 01,2026 To June 04,2026

June 1, 2026

Bernstein’s 42nd Annual Strategic Decisions Conference May 27,2026 To May 29,2026 May 27 May 28 May 29 All logos and trademarks remain the intellectual properties of their respective owners

Attention stay up to date with the latest investor calls by checking out our calendar for the week of May 27,2026 To May 29,2026

May 26, 2026

« Previous Page1 Page2 Page3 Page4 Page5 Next »

Healthcare Insights

WORLD THALASSEMIA DAY HIDDEN NO MORE - Finding the Undiagnosed, Supporting the Unseen AN INHERITED HEMOGLOBIN DISORDER Thalassemia is a genetic condition caused by mutations in globin genes that lead to an imbalance of α- and β-globin chains, resulting in red blood cell destruction The 2026 Global Mission: To identify undiagnosed individuals and support those whose daily challenges remain unrecognized by society & healthcare systems Global Lighting Initiative "Bring To Light" movement encourages cities to illuminate iconic landmarks in red to symbolize solidarity and advocacy Alpha vs. Beta Thalassemia PREVALENCE Alpha Beta Alpha types involves deletions on chromosome 16 Beta types usually involve point mutations on chromosome 11 Minor vs. Major (TDT vs. NTDT) 1.3 M Global Cases Among them, 400,000 children are born with severe forms annually Mild Severe Minor/Trait Major/Transfusion-Dependent Often asymptomatic carriers Requires lifelong blood support for survival THALASSEMIA BELT REGIONS SYMPTOMS & COMPLICATIONS Chronic fatigue Pale skin Jaundice Shortness of breath Bone deformities Growth retardation THE TREATMENT REVOLUTION CASGEVY REBLOZYL Cell-based gene therapy Erythroid maturation agent The Danger of Iron Overload STANDARD CARE: TRANSFUSIONS & CHELATION Frequent transfusions can lead to iron accumulation, causing and organ damage Regular blood transfusions to maintain hemoglobin levels and iron chelation therapy to remove excess iron from the body Vyuhpharma® All Rights Reserved Note: This report is generated based on publicly available data

Every drop of awareness brings hope ❤️On World Thalassemia Day, we work together to create awareness on thalassemia, encourage early diagnosis and better access to care, and support patients and their families Together, we can help build a healthier and stronger future for every life affected by thalassemia

May 8, 2026

WORLD ASTHMA DAY MAY 5, 2026 BREATHE EASY , LIVE FULLY What Is Asthma? It is a chronic, non-communicable, inflammatory condition.That causes the airways in the lungs to swell, narrow, and produce extra mucus. ASTHMA CAN AFFECT ANYONE, AT ANY AGE 363M to 434M High Total Globally Approximately Prevalent in Children & Adolescents, Particularly Aged 5–9 and 10–17 Years, respectively 442L to 450L Total Mortality Low Adolescents Children 5–9 Yrs 10–17 Yrs Key Insight: Over 90% of deaths occur in low-to-middle income countries due to a lack of access to inhaled corticosteroids Low prevalence High prevalence Moderate prevalence Types of Asthma Allergic Asthma Non-Allergic Asthma Occupational Asthma Exercise-Induced Bronchoconstriction Cough-Variant Asthma Aspirin-Induced Asthma Common Tiggers Asthma Symptoms Air pollution Allergens Tobacco smoke Infection Physical activity Emotional stress Wheezing Shortness of Breath Chest Tightness Persistent Cough Key Management Strategy Microscopic View Healthy Airway Severe Asthma Airway smooth muscle: Hyperresponsiveness Constriction Thickening Early diagnosis and regular monitoring Adherence to prescribed medications Avoidance of known triggers Patient education awareness Asthma action plan Subepithelial inflammation and fibrosis Mucus hypersecretion and impaired mucus clearance Treatment Regimen Main Role Top Examples Medication Increased eosinophils and/or neutrophils in airway lumen Daily Controller (ICS) Prevents swelling/mucus Pulmicort, Arnuity, QVAR Combination (ICS+LABA) Long-term control + open airways Symbicort, Breo, Dulera AIR / MART Therapy One inhaler for daily use Symbicort (Budesonide/Formoterol) Quick Reliever (SABA) Immediate "emergency" relief Albuterol (Ventolin, ProAir) Add-on (LAMA/LTRA) Extra support for difficult symptoms Spiriva, Singulair Biologics Targeted injections for severe cases Dupixent, Tezspire, Exdensur Oral Steroids (OCS) Short-term "reset" for major flares Prednisone Bronchial Comparison Air trapped in alveoli Relaxed smooth muscles Tightened smooth muscles Wall inflamed and thickened Asthmatic airway during attack Normal airway Asthmatic airway

On World Asthma Day 2026, we stand for every breath, every life that matters.Asthma affects millions worldwide; yet, with the right awareness, early diagnosis and consistent care, it can be managed effectively.Let’s work together to create environments that support healthier lungs and better lives.

May 5, 2026

World Parkinson’s Day 2026 Substantia nigra (Dopamine producing cells) Dopamine levels in normal neuron Parkinson’s disease (PD) is a neurodegenerative disorder that predominantly affects the dopamine-producing “dopaminergic” neurons, in specific area of the brain called the substantia nigra Lewy body inclusion Diffuse α-synuclein aggregates Motor Neuron Receiving neuron Transmitting neuron Dopamine receptor Dopamine Cellular Pathology Oligomerization α-synuclein monomer Mature Lewy body inclusion α-synuclein protofibril oligomer α-synuclein fibril aggregates Autocatalytic process Dopamine levels in PD affected neuron High PD symptoms Non-motor symptoms Motor symptoms 25.2M people with PD disease globally by 2050 Depression, anxiety, cognitive impairment Low Stooped posture Masked face Back rigidity Forward tilt Flexed elbows and wrists Loss of smell Prevalence of PD in the US Hand tremor Gastrointestinal symptoms M Flexed hip and knees W Tremors in legs 1.2M (2030) Americans will be living with PD 54% 46% 80+ 60-79 40-59 Joint pain Shuffling, short stepped gait (Age 80+) Age groups Clinical symptoms and time course of PD progression Early stages PD Diagnosis Advanced stages Prodromal period Impaired balance, functioning intact Both sides affected but balance remains One side of the body is affected Constipation RBD Walking and standing difficult without help Wheelchair-bound or bed-ridden -10 0 -20 10 20 PD management Diagnosis Symptomatic Treatment No Disease-modifying therapies (DMT) approved HIGH UNMNET NEED PERSISTS MAO-B inhibitors (MAOBi): Rasagiline, Selegiline Levodopa-Carbidopa: Standard fixed dose Prodrug formulations: Foslevodopa/ Foscarbidopa MRI PET scan SNCA LRRK2 GBA Blood & CSF Biomarkers MDS-UPDRS PDQ-39 "ON/OFF" Time Deep-Brain Stimulation (DBS) DBS for stronger symptom relief Neuroimaging Assessments Genetic tests Laboratory tests Vyuhgenics®, ISO 27001 & 9001 certified Note: This report is generated based on publicly available data

This World Parkinson’s Day, we stand united to amplify awareness and drive meaningful change. Parkinson’s is more than a condition—it’s a journey that impacts millions of lives. By supporting research, innovation, and compassionate care, we move one step closer to a better future. Together, let’s turn awareness into action.

April 11, 2026

« Previous Page1 Page2 Page3 Page4 Page5 Next »

The Pharma BI division of

Vyuhgenics Inc.

Henderson, Nevada, USA – 89014

Vyuhpharma ®, All Rights Reserved.

Sitemap

Terms of use

Connect with us

Please fill in the information below, and we'll get back to you.

Full Name

Email Address

Your Company

Contact

Your message